Evidence map›Paper›PMID 41719158›Full record

ArticleCancer immunology research2026

Potent Cytotoxic Tumor-Infiltrating Lymphocytes Can Be Generated from Immune-Excluded Chondrosarcomas Using Regulatable Membrane-Bound IL15.

Zheng Ao, Rusul Al-Marayaty, Bulent Arman Aksoy, Farres Obeidin, Rachel Burga, Samer Attar, Terrance Peabody, Pedro Hermida de Viveiros, Juliana Chi Kei Ng, Weiqing Jing and 11 more

Abstract read
In one paragraph

Article in Cancer immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Zheng AoObsidian Therapeutics, Cambridge, Massachusetts.ORCID 0000-0002-8459-8198
Rusul Al-MarayatyNorthwestern University , Feinberg School of Medicine, Chicago, Illinois.ORCID 0000-0002-5851-0121
Bulent Arman AksoyObsidian Therapeutics, Cambridge, Massachusetts.ORCID 0000-0002-0135-2505
Farres ObeidinNorthwestern University , Feinberg School of Medicine, Chicago, Illinois.ORCID 0000-0001-8461-9238
Rachel BurgaObsidian Therapeutics, Cambridge, Massachusetts.ORCID 0000-0002-0204-8986
Samer AttarNorthwestern University , Feinberg School of Medicine, Chicago, Illinois.ORCID 0000-0001-6956-7652
Terrance PeabodyNorthwestern University , Feinberg School of Medicine, Chicago, Illinois.ORCID 0000-0002-6669-4549
Pedro Hermida de ViveirosNorthwestern University , Feinberg School of Medicine, Chicago, Illinois.ORCID 0009-0008-5449-0726
Juliana Chi Kei NgNorthwestern University , Feinberg School of Medicine, Chicago, Illinois.ORCID 0000-0002-0142-2278
Weiqing JingNorthwestern University , Feinberg School of Medicine, Chicago, Illinois.ORCID 0000-0002-3008-9873
Himaly ShinglotNorthwestern University , Feinberg School of Medicine, Chicago, Illinois.ORCID 0000-0001-7726-8417
Ali ZhangNorthwestern University , Feinberg School of Medicine, Chicago, Illinois.ORCID 0000-0003-1275-075X
Alonso Villasmil OcandoObsidian Therapeutics, Cambridge, Massachusetts.ORCID 0009-0007-0784-0095
Nishita RoyObsidian Therapeutics, Cambridge, Massachusetts.ORCID 0009-0009-8414-0046
Gauri KulkarniObsidian Therapeutics, Cambridge, Massachusetts.ORCID 0009-0001-2532-2327
Andres AlvaradoObsidian Therapeutics, Cambridge, Massachusetts.ORCID 0009-0001-2908-336X
Dexue SunObsidian Therapeutics, Cambridge, Massachusetts.ORCID 0009-0003-5214-4831
Dhruv K SethiObsidian Therapeutics, Cambridge, Massachusetts.ORCID 0009-0000-5790-456X
Michelle OlsObsidian Therapeutics, Cambridge, Massachusetts.ORCID 0000-0002-5827-7032
Jan Ter MeulenObsidian Therapeutics, Cambridge, Massachusetts.ORCID 0000-0001-9396-9686
Seth M PollackNorthwestern University , Feinberg School of Medicine, Chicago, Illinois.ORCID 0000-0002-2466-0607

Funding

Novel IL-12 Gene Delivery Vehicles for Transformation of Solid TumorsR01CA244872 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI POLLACK, SETH M · 2020 to 2024
$2.5M
Special Public T Cell Receptor Sequences that Predict Outcomes for Cancer PatientsR21CA277285 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI POLLACK, SETH M · 2023 to 2024
$402k
National Cancer Institute (NCI) R01CA244872NCI NIH HHS R01 CA244872NCI NIH HHS R21 CA277285
6 · The paper itself

Abstract

Autologous tumor-infiltrating lymphocyte (TIL) cell therapy is showing promising efficacy against immunologically "hot" tumors such as melanoma, cervical cancer, and renal cancer. However, generation of tumoricidal TILs from "cold" tumors with a low tumor mutational burden, such as many sarcoma types, poses a challenge due to limited infiltration of the tumor microenvironment (TME) with lymphocytes, low frequencies of tumor antigen-specific, high-affinity T cells, and incompletely understood mechanisms of immune-resistance prevailing in the TME. Here, we report the successful generation and expansion of TILs engineered with regulatable, membrane-bound IL15 (cytoTIL15 cells) from immune-excluded, paucicellular chondrosarcoma biopsies largely consisting of collagenous matrix and demonstrate that these cells have potent tumor-killing capacity in cell culture and in tumor spheroid models in the absence of exogenous IL2. Comprehensive spatial profiling of the TME revealed ubiquitous collagen and myeloid infiltration as major resistance mechanisms, whereas lymphocytic infiltration was largely restricted to peripheral regions of the tumors, a relevant consideration when sampling these tumors for TIL harvest. Moreover, we demonstrate that IL15 reduced the signaling threshold of T-cell receptors isolated from TIL clonotypes, increasing their infiltration and cytotoxicity in autologous 3D tumor models. These results suggest the possibility of developing an effective IL2-free TIL therapy for patients with immune-excluded tumors.

Indexed as

Bone NeoplasmsChondrosarcomaInterleukin-15Lymphocytes, Tumor-InfiltratingT-Lymphocytes, CytotoxicAnimalsCell Line, TumorCytotoxicity, ImmunologicHumansTumor MicroenvironmentIL15 protein, humanInterleukin-15

Identifiers

PMID41719158
PMCPMC13227094

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.